e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Management of airway disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
What represents a meaningful improvement in symptom-free days (SFD) and rescue-free days (RFD)? The patient‘s perspective
S. Martin, R. Stanford, P. Dale, S. Fehnl (Ann Arbor, RTP, United States Of America; London, United Kingdom)
Source:
Annual Congress 2010 - Management of airway disease
Session:
Management of airway disease
Session type:
Thematic Poster Session
Number:
4555
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Martin, R. Stanford, P. Dale, S. Fehnl (Ann Arbor, RTP, United States Of America; London, United Kingdom). What represents a meaningful improvement in symptom-free days (SFD) and rescue-free days (RFD)? The patient‘s perspective. Eur Respir J 2010; 36: Suppl. 54, 4555
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Asthma control (AC) and quality of life (QoL) 3 months after pulmonary rehabilitation (PR)
Source: Annual Congress 2010 - Pulmonary rehabilitation: understanding and developing the intervention
Year: 2010
The incremental shuttle walk test (ISW) in patients with bronchiectasis: Response to pulmonary rehabilitation (PR) and minimum clinically important difference (MCID)
Source: International Congress 2019 – Hot topics in pulmonary rehabilitation
Year: 2019
An increase in steps per day 6 weeks after pulmonary rehabilitation of COPD patients correlates with an improvement in quality of life
Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation
Year: 2020
Fluticasone/salmeterol combination (FSC) is safe and provides effective long-term (52 week) control in the management of patients with persistent asthma (PA)
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001
Minimal clinically important differences for Dyspnea-12 and MDP scores are similar at 2 weeks and 6 months: follow-up of a longitudinal clinical study
Source: Eur Respir J, 57 (3) 2002823; 10.1183/13993003.02823-2020
Year: 2021
Dose selection and pharmacokinetics of montelukast (sprinkles) in >=6 month to <2 year old asthmatic patients
Source: Eur Respir J 2002; 20: Suppl. 38, 525s
Year: 2002
Decline in 4-metre gait speed (4MGS) over 6 months is associated with mortality in IPF.
Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia
Year: 2019
LATE-BREAKING ABSTRACT: The minimal clinically important difference (MCID) for the six minute walk (6MW) test in COPD in relation to death
Source: Annual Congress 2012 - The latest insights in chronic care
Year: 2012
Who win? Spirometry versus symptoms for predicting the longitudinal outcomes in COPD patients – 10 years observation
Source: Annual Congress 2011 - Clinical parameters in airway diseases
Year: 2011
Trajectory of patient-reported outcomes (PROMs) up to 6 months after hospitalization for SARS-CoV-2
Source: Virtual Congress 2021 – Long COVID - 19
Year: 2021
Influence of an incentive spacer on adherence to prescribed treatment in 2-6 year old children over a 3 month period
Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up
Year: 2007
Sustainability of use of an electronic health journal (patientMpower) for pulmonary fibrosis in a US patient support group (PF Warriors) over 180 days.
Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias
Year: 2018
Degree of exercise limitation in COPD: impact on 6 minute walk (6MW) in response to long-acting β-agonist (LABA) treatment
Source: Eur Respir J 2007; 30: Suppl. 51, 76s
Year: 2007
Indacaterol/glycopyrronium (IND/GLY) reduces days with COPD exacerbation vs salmeterol/fluticasone (SFC) independent of PRO tool: results of the FLAME study
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017
Changes in subjective assessments during 2 and 4 weeks of a nasal CPAP (nCPAP) trial?
Source: Eur Respir J 2002; 20: Suppl. 38, 101s
Year: 2002
LATE-BREAKING ABSTRACT: RESPIRE 1: Ciprofloxacin DPI 32.5mg b.d. administered 14 day on/off or 28 day on/off vs placebo for 48 weeks in subjects with non-cystic fibrosis bronchiectasis (NCFB)
Source: International Congress 2016 – Clinical update on bronchiectasis
Year: 2016
Longterm [7 year] follow-up of patients fitted with a non-adjustable intra-oral device (IOD) for snoring/obstructive sleep apnoea (OSAS)
Source: Eur Respir J 2004; 24: Suppl. 48, 477s
Year: 2004
Montelukast is safe and well tolerated in >=6 month to <2 year old patients
Source: Eur Respir J 2002; 20: Suppl. 38, 525s
Year: 2002
How does regular exercise affect dyspnoe (TDI) and quality of life (CAT) of COPD-patients 1 year after an inpatient pulmonary rehabilitation (PR)?
Source: International Congress 2015 – Latest insights into pulmonary rehabilitation
Year: 2015
Efficacy, safety and tolerability of 3 day azithromycin (A)
versus
10-day conventional treatment (CT) in the treatment of children with acute asthma exacerbation (AE)
Source: Eur Respir J 2005; 26: Suppl. 49, 135s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept